Sortina Pharma AB has appointed Sara Rhost as CEO

portrait of Sara Rhost, CEO of Sortina Pharma

Sara has a doctoral degree in immunology from Gothenburg University and has been managing and driving the sortilin-project from research into product development. She has extensive experience in cancer research and has been one of the lead scientists for the sortilin-project initiated at the University of Gothenburg. She has co-founded Sortina Pharma together with professor Göran Landberg and GU Ventures in 2020.

Previous
Previous

Sortina Pharma AB announces the appointment of new members to its Board of Directors

Next
Next

Clinical article: Berger et al 2021 BMC Cancer